(Q36161293)

12 August 2017

1 reference

title

Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD. (English)

1 reference

12 August 2017

Richard H Weisler

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

1003-1018

1 reference

Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Pemoline-associated hepatic failure: a critical analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Adolescents with attention-deficit/hyperactivity disorder: an overview of empirically based treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Attention Deficit Disorder and hospitalization due to injury among older adolescents in New South Wales, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Attention deficit hyperactivity disorder and suicide: a review of possible associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Psychiatric disorders and attempted suicide among adolescents with substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Driving outcomes of young people with attentional difficulties in adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Treatment of attention-deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Cardiovascular effects of atomoxetine in children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

Attention-deficit/hyperactivity disorder and comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

The 4-Year Course of Tic Disorders in Boys With Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.6.1003

10.1517/14656566.6.6.1003

21 January 2018

Identifiers

DOI

1 reference

release_f5x6x5gl6vhl3jeoutry2wu6gm

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f5x6x5gl6vhl3jeoutry2wu6gm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference